Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867045 · ClinicalTrials.gov registry record · NA
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03867045: Clinical Trial NA study, sponsored by Duke University.
NCT03867045 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03867045, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.
Primary Outcome
Number of comments from participants indicating ease of use of the application.
Interventions
- DEVICE Usability of an electronic symptom management application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-08-21 |
| Est. Completion | 2019-12-16 |
| Phase | NA |
Why NCT03867045 stopped before completion
NCT03867045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Usability of an electronic symptom management application is the first listed.
NCT03867045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03867045 about?
NCT03867045 is a clinical study titled "Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer". The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.
What is the current status of trial NCT03867045?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2019-08-21. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT03867045?
The interventions under investigation include: Usability of an electronic symptom management application (DEVICE).
Who is sponsoring clinical trial NCT03867045?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03867045's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI